Sant Muangnoicharoen

420/6 Ratchawithi Road
Ratchathewi, 10400, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Delayed diagnosis of Plasmodium vivax malaria and associated factors among Thai patients and patients from neighboring countries at the Hospital for Tropical Diseases, Bangkok, Thailand.

Delayed diagnosis of Plasmodium vivax malaria and associated factors among Thai patients and patients from neighboring countries at the Hospital for Tropical Diseases, Bangkok, Thailand.

Journal: Infection

Published: June 20, 2026

Ultrasound-Based Staging and Its Impact on Clinical Management of Hepatic Hydatid Cysts in an Endemic Setting: A Cross-Sectional Study in Eastern Afghanistan.

Ultrasound-Based Staging and Its Impact on Clinical Management of Hepatic Hydatid Cysts in an Endemic Setting: A Cross-Sectional Study in Eastern Afghanistan.

Journal: Tropical medicine and infectious disease

Published: May 19, 2026

Long-term effectiveness of at least one dose of human papillomavirus vaccine in adolescents: A test-negative case-control study.

Long-term effectiveness of at least one dose of human papillomavirus vaccine in adolescents: A test-negative case-control study.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: January 05, 2026

Prevalence, infection status and associated factors of H. Pylori among adult dyseptic patients in Jalalabad, Afghanistan.

Prevalence, infection status and associated factors of H. Pylori among adult dyseptic patients in Jalalabad, Afghanistan.

Journal: BMC infectious diseases

Published: October 27, 2025

Rifampicin-resistant tuberculosis in Nangarhar, Afghanistan: prevalence and risk factors.

Rifampicin-resistant tuberculosis in Nangarhar, Afghanistan: prevalence and risk factors.

Journal: BMC infectious diseases

Published: October 20, 2025

One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand.

One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand.

Journal: NPJ vaccines

Published: August 13, 2025

Prevalence and associated factors of intestinal parasitic infections among schoolchildren in Jalalabad, Afghanistan.

Prevalence and associated factors of intestinal parasitic infections among schoolchildren in Jalalabad, Afghanistan.

Journal: BMC infectious diseases

Published: July 29, 2025

Immune responses after two inactivated COVID-19 vaccine doses, a heterologous third dose and subsequent boosting with bivalent mRNA in adults.

Immune responses after two inactivated COVID-19 vaccine doses, a heterologous third dose and subsequent boosting with bivalent mRNA in adults.

Journal: Scientific reports

Published: July 21, 2025

Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S).

Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S).

Journal: Vaccine

Published: December 17, 2024

Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.

Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.

Journal: Vaccine

Published: January 07, 2024

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.

Journal: Vaccine

Published: February 22, 2023

An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.

An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.

Journal: Science translational medicine

Published: February 15, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026